China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Director of Tenax Therapeutics (NASDAQ:TENX), Almenoff June Sherie, reported purchasing a total of 1993 shares of common stock in two transactions. The shares were bought at prices ranging from $7.15 to $7.5157, with the total value of the purchases amounting to $14944. This insider buying comes as TENX shares have shown strong momentum, with a 50.62% return over the past year and a 21.59% gain over the last six months, according to InvestingPro data.
On November 17, 2025, Almenoff bought 93 shares at $7.15 per share. This was followed by another purchase on November 18, 2025, of 1900 shares, executed in multiple trades at prices ranging from $7.45 to $7.70. Currently trading at $7.32, TENX appears slightly overvalued compared to its InvestingPro Fair Value. Analysts remain optimistic, with price targets ranging from $10 to $30, suggesting potential upside from current levels. InvestingPro identifies 15 additional investment tips for Tenax Therapeutics, including insights on financial health and growth prospects.
The Director also declared holdings in Stock Options: 4 shares at an exercise price of $3200, 4 shares at an exercise price of $992, 100000 shares at an exercise price of $5.94 and 80000 shares at an exercise price of $5.75. With a market capitalization of $297.38 million and a "FAIR" financial health score according to InvestingPro metrics, Tenax Therapeutics continues to attract insider confidence despite its volatile price movements.
In other recent news, Piper Sandler has initiated coverage on Tenax Therapeutics with an Overweight rating. The firm has set a price target of $20.00 for the company. This development comes as Tenax Therapeutics continues its work on TNX-103, an oral treatment for pulmonary hypertension with heart failure with preserved ejection fraction. The company is anticipating results from its Phase 3 LEVEL trial in the second half of 2026. Piper Sandler’s positive outlook reflects confidence in Tenax’s ongoing research and development efforts. Investors may find this information relevant as they consider the potential of Tenax’s treatment pipeline. The initiation of coverage by Piper Sandler marks a significant step for Tenax in the eyes of the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.